The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 27, 2021

Filed:

Feb. 12, 2018
Applicant:

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, CN;

Inventors:

Youhong Hu, Shanghai, CN;

Meiyu Geng, Shanghai, CN;

Wenming Ren, Shanghai, CN;

Jian Ding, Shanghai, CN;

Xiaocong Guan, Shanghai, CN;

Jing Ai, Shanghai, CN;

Lang Wang, Shanghai, CN;

Xia Peng, Shanghai, CN;

Yang Liu, Shanghai, CN;

Yang Dai, Shanghai, CN;

Limin Zeng, Shanghai, CN;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/12 (2006.01); C07D 405/14 (2006.01); C07D 403/12 (2006.01); A61P 35/00 (2006.01); B01J 31/24 (2006.01); B01J 27/122 (2006.01); B01J 31/30 (2006.01);
U.S. Cl.
CPC ...
C07D 401/12 (2013.01); A61P 35/00 (2018.01); B01J 27/122 (2013.01); B01J 31/2409 (2013.01); B01J 31/30 (2013.01); C07D 403/12 (2013.01); C07D 405/14 (2013.01); B01J 2231/44 (2013.01); B01J 2531/007 (2013.01); B01J 2531/824 (2013.01);
Abstract

An o-aminoheteroaryl alkynyl-containing compound has a structure represented by formula (I), and the compound of formula (I) has advantages of a high FGFR and RET double target inhibitory activity and a relatively low KDR activity, and the compound of formula (I) exhibits a strong inhibitory activity in a human lung cancer cell line NCI-H1581 and a gastric cancer cell line SNU16 as well as an RET-dependent sensitive cell line BaF3-CCDC6-Ret and a mutant thereof. Pharmacokinetic data shows that the o-aminoheteroaryl alkynyl-containing compound has druggability, and exhibits significant relevant inhibition of the growth of related tumors in a long-term animal model of drug efficacy and results in favorable animal condition at effective doses.


Find Patent Forward Citations

Loading…